Navigation Links
New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
Date:9/6/2007

MANHASSET, N.Y., Sept. 6 /PRNewswire-USNewswire/ -- Scientists at The Feinstein Institute for Medical Research have identified a critical gene that increases a person's risk for rheumatoid arthritis and systemic lupus erythematosus, and may be involved with other autoimmune diseases.

The genetic link, described in the September 6th issue of the New England Journal of Medicine, was a collaborative effort led by Peter K. Gregersen, MD, head of The Feinstein Institute's Robert S. Boas Center for Genomics & Human Genetics. A decade ago, Dr. Gregersen helped bring together scientists from a dozen institutes to pool patients and add strength in numbers as they collectively hunt for genes. More recently, the North American Rheumatoid Arthritis Consortium (NARAC) studied a region identified on chromosome 2 in previous linkage studies conducted by the same team. In the latest study, they analyzed DNA from 2,500 patients with rheumatoid arthritis (RA) or lupus. Genetic mapping enabled them to identify STAT4 as a culprit in susceptibility to both diseases.

"This work required the collection and genotyping of thousands of RA and lupus patients and volunteers, a task that would have been difficult to accomplish without the strong partnerships we forged," said Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The federal institute has supported NARAC since its inception.

"Identifying STAT4 as the relevant gene on chromosome 2 is very exciting," added Elaine Remmers, PhD, a lead author in the NEJM study on STAT4 and a staff scientist in the NIAMS's Genetics and Genomics Branch. "We now are faced with trying to figure out how this variant of STAT4 increases a person's risk."

About 22 percent of people in the United States inherit this particular form of STAT4. Having this variant of STAT4 confers a 30 percent increased risk for developing rheumatoid arthritis. People with two copie
'/>"/>

SOURCE The Feinstein Institute for Medical Research
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
3. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
4. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
5. Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
8. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
9. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
10. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... 1 CeloNova BioSciences, Inc., a p...l devices and of specialty implants, today announc...er and medical director of Baptist Cardiac & V...the CATANIA(TM) Stent System with NanoThin Polyzen...erventions Conference to be held at the Hotel Davi...
(Date:12/1/2009)..., Dec. 1 Cumberland Phar...that an independently conducted study of Acetadote...etylcysteine, as a cost-saving treatment for aceta...ber 4 of the peer-reviewed Journal of Medical Eco...ludes that Acetadote is a less costly treatment re...
(Date:12/1/2009)...1 CCS Medical, Inc. a leading dire... announced that it has received approval from the ...aware (the "Court") for its bidding procedures in ... substantially all of its assets. ,, Pursuant t...oved bidding procedures for the sale of substantia...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 2Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 3Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 4Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 5Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 6CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 263 percent of RA patients suffer psychiatric disorders with depressive spectrum conditions most likely 48746 163 percent of RA patients suffer psychiatric disorders with depressive spectrum conditions most likely 48746 2Promising device snags young inventors coveted spot at IShow 8813 1Promising device snags young inventors coveted spot at IShow 8813 2Promising device snags young inventors coveted spot at IShow 8813 3Rainforest rehab in every sense 8811 1Rainforest rehab in every sense 8811 2
...ILADELPHIA, Nov. 7 Data from an investigational,o...ing regimens of,PROCRIT(R) (Epoetin alfa) in treat...idney disease (CKD) were presented today at the Am... All three dosing groups, including the FDA-appro...a-week (QW) and,once-every-two-weeks (Q2W) investi...
...N DIEGO, Nov. 6 Cadence Pharmaceuticals,Inc. (Nas...on in-licensing,developing and commercializing pro... the hospital setting, today reported financial re...September 30, 2008., The company also provided an...ts two Phase III product candidates -- Acetavance(...
Other Medicine Technology:Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 2Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 3Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 4Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 5Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 7Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 8
(Date:12/2/2009)...ucts Inc., an industry leader in healthcare produc...opening of its new headquarters in the Irvine Spec... Drive, Irvine, California 92618. In addition, Lin...e Spectrum plus an assembly and distribution opera...ion reflects Links Medical,s rapid growth and the ...
(Date:12/2/2009)...ed by Suzanne Somers in her N.Y. Times #1 best-sel... NY (PRWEB) December 2, 2009 -- In her new book KN...cer, And How to Prevent Getting It in the First Pl...cessfully using the most innovative cancer treatme... tear it down. This is a subject Somers writes abo...
(Date:12/2/2009)...vails in counterclaim against three plaintiffs who...ess dispute over work done on hotel construction p...xis Nexis) December 2, 2009 -- The Tampa-based law...ed the settlement of a two-year legal dispute that...t, ConArt, Inc., , ,ConArt, a Georgia-based precas...
(Date:12/2/2009)...eves IBM Ready for LINUX designation and enhances ...nframe and contemporary systems running Linux. , ...er 2, 2009 -- eCube Systems, a leader in legacy ev...nced that it has achieved the IBM Ready for LINUX ...ware. This mark certifies NXTera has met compatib...
(Date:12/2/2009)...PRNewswire/ -- Last month on a prominent nationall...ate Professor at the Stanford Sleep Disorders Clin...mmended the Ecotones Duet Sleep Sound Machine as p...chieve a better night,s sleep with minimal use of ...ople when they are sleeping," said Dr. Pelayo. "Th...
Breaking Medicine News(10 mins):Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 2Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Gallagher Keenan Obtains $500,000 Settlement for ConArt, Inc. in Dispute with Florida Hotel Companies 2Health News:eCube Delivers Linux on System z Support for NXTera High Performance Middleware 2Health News:eCube Delivers Linux on System z Support for NXTera High Performance Middleware 3Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3
...organization analyzed a government survey conducte...n //who had come for having an abortion said they ...d come for repeat abortions were found to be over ...t. Abortions are not uncommon these days and...
...e of drugs such as heroin and crack impacts the ec...?15 billion a year. // These costs were delin...ims, police, court and NHS costs. The European dru... that brown heroin was cheaper by 47% and ecstasy ...
...at, in order to implement better cancer care to pa...tely. //Their views were published in the British ...at the National Institute for Health and Clinical ...to ensure that those battling with cancer shall be...
... Minister for Ageing, Senator Santo Santoro, to di...ies, //as set out in the AMA's Federal Budget Subm...e Medicare Benefits Schedule (MBS) makes it very d...eral practitioners able to visit residential aged ...
...ned to raise its legal age for buying cigarettes f...y said //that the new legislation would go into ef...ollowing the recommendations made by an expert gro...rs and introducing negative licensing law, which w...
...interesting study on longevity. Doctors from the U...n to mothers before they turn 25 were twice more l...kids born to mothers who are older. Researche...mother as well as the order of the birth. The rese...
Other Medicine News:Health News:Cancer Care Compromised by Cost 2
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: